Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M136,555Revenue $M37,075Net Margin (%)10.7Z-Score2.5
Enterprise Value $M140,551EPS $1.8Operating Margin %14.6F-Score4
P/E(ttm))61.9Cash Flow Per Share $0Pre-tax Margin (%)13.2Higher ROA y-yN
Price/Book2.310-y EBITDA Growth Rate %2.7Quick Ratio1.3Cash flow > EarningsY
Price/Sales7.65-y EBITDA Growth Rate %-2.5Current Ratio1.8Lower Leverage y-yN
Price/Cash Flow0y-y EBITDA Growth Rate %-0.7ROA % (ttm)3.8Higher Current Ratio y-yY
Dividend Yield %3.7Insider Buy (3m)0ROE % (ttm)6.5Less Shares Outstanding y-yN
Payout Ratio %84.0Shares Outstanding M2,639ROI % (ttm)4.2Gross Margin Increase y-yN

Gurus Latest Trades with SNY

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
SNYHOTCHKIS & WILEY 2014-12-31 Add0.29%$44.4 - $55
($48.49)
$ 51.756%Add 18.16%11,692,693
SNYNWQ Managers 2014-12-31 Add0.29%$44.4 - $55
($48.49)
$ 51.756%Add 22.12%2,941,923
SNYCharles Brandes 2014-12-31 Add0.21%$44.4 - $55
($48.49)
$ 51.756%Add 14.36%2,571,795
SNYJames Barrow 2014-12-31 Add0.15%$44.4 - $55
($48.49)
$ 51.756%Add 8.87%30,804,459
SNYDavid Dreman 2014-12-31 Buy $44.4 - $55
($48.41)
$ 51.756%New holding1,102
SNYBill Nygren 2014-09-30 Add0.27%$50.89 - $57.29
($53.73)
$ 51.75-4%Add 14.55%5,670,000
SNYJean-Marie Eveillard 2014-09-30 Reduce-0.07%$50.89 - $57.29
($53.73)
$ 51.75-4%Reduce -94.39%34,157
SNYNWQ Managers 2014-06-30 Reduce-1.31%$51.23 - $54.54
($53.08)
$ 51.75-3%Reduce -52.34%2,602,503
SNYBill Nygren 2014-06-30 Add0.9%$51.23 - $54.54
($53.08)
$ 51.75-3%Add 90.38%4,950,000
SNYBill Nygren 2014-03-31 Buy 1.1%$47.77 - $53.63
($50.68)
$ 51.752%New holding2,600,000
SNYHOTCHKIS & WILEY 2014-03-31 Add0.75%$47.77 - $53.63
($50.68)
$ 51.752%Add 65.83%9,804,594
SNYJames Barrow 2014-03-31 Add0.39%$47.77 - $53.63
($50.68)
$ 51.752%Add 22.72%27,790,116
SNYNWQ Managers 2014-03-31 Reduce-0.17%$47.77 - $53.63
($50.68)
$ 51.752%Reduce -6.39%5,460,055
SNYHOTCHKIS & WILEY 2013-12-31 Add0.27%$48.75 - $54
($51.57)
$ 51.750%Add 23.53%5,912,375
SNYCharles Brandes 2013-12-31 Add0.2%$48.75 - $54
($51.57)
$ 51.750%Add 18.29%2,013,300
SNYNWQ Managers 2013-12-31 Add0.19%$48.75 - $54
($51.57)
$ 51.750%Add 7.52%5,832,760
SNYMario Gabelli 2013-12-31 Reduce$48.75 - $54
($51.57)
$ 51.750%Reduce -24.37%4,500
SNYJames Barrow 2013-09-30 Add1.29%$47.64 - $53.24
($50.87)
$ 51.752%Add 312.86%21,466,988
SNYHOTCHKIS & WILEY 2013-09-30 Add0.26%$47.64 - $53.24
($50.87)
$ 51.752%Add 31.71%4,786,334
SNYMario Gabelli 2013-09-30 Add$47.64 - $53.24
($50.87)
$ 51.752%Add 32.22%5,950
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

SNY is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


SNY: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Sanofi10% Owner 2015-01-29Buy97,118$95-45.52view
Sanofi10% Owner 2015-01-26Buy647,448$95-45.52view
Sanofi10% Owner 2015-01-22Buy196,251$93.17-44.45view
Sanofi10% Owner 2014-03-25Buy344,448$66.88-22.61view
Sanofi10% Owner 2014-02-04Buy1,303,780$7.67574.84view

Press Releases about SNY :

    Quarterly/Annual Reports about SNY:

      News about SNY:

      Articles On GuruFocus.com
      Mt Stocks Apr 19 2015 
      Scottrade Mar 22 2015 
      Pfizer In The Process Of Making Path Breaking Vaccine Mar 18 2015 
      Oh là là! Looking for Dividend Yield? Explore France Feb 27 2015 
      FDA Approves Sanofi’s New Diabetes Drug Feb 27 2015 
      Dodge & Cox 2014 Equity Year in Review Feb 19 2015 
      The Reasons That Make Pfizer A Worthy Hold. Feb 05 2015 
      Causeway Capital Global Value Equity Q4 2014 Commentary Feb 04 2015 
      Causeway International Value Fund Q4 2014 Commentary Jan 20 2015 
      Dodge & Cox's Stock Fund Q4 2014 Commentary Jan 20 2015 


      More From Other Websites
      Sanofi: Effect of Genzyme's Multiple Sclerosis Treatment Lemtrada® (alemtuzumab) on Slowing Brain... Apr 23 2015
      9:01 am Sanofi-Aventis: Effect of Genzyme's multiple sclerosis treatment Lemtrada (alemtuzumab) on... Apr 23 2015
      Effect of Genzyme’s Multiple Sclerosis Treatment Lemtrada® (alemtuzumab) on Slowing Brain Atrophy... Apr 23 2015
      Alnylam Reports Positive Patisiran Results, Shares Up - Analyst Blog Apr 22 2015
      How a Stronger US Dollar Has Affected Large-Cap Stocks Apr 22 2015
      Amgen: But What About the Biosimilars? Apr 22 2015
      Sanofi-Aventis upgraded by Citigroup Apr 22 2015
      Genzyme Initiates Phase 2a Clinical Trial to Evaluate Oral Therapy for Fabry Disease Apr 21 2015
      Bristol's Opdivo Scores Again Against Lung Cancer Apr 17 2015
      Actelion to Boost Progress of Specialty Immunology Pipeline - Analyst Blog Apr 16 2015
      The Medicines Co.'s Kengreal Briefing Documents Positive - Analyst Blog Apr 14 2015
      Fewer CEOs Fired and More Retired Save Shareholders Billions Apr 13 2015
      Fewer CEOs Are Being Fired and That's Good News for Shareholders Apr 13 2015
      Wave of interest in gene therapy brings Voyager a new $60M investment Apr 13 2015
      Genzyme to Present New Long-Term Data on Aubagio® (teriflunomide) and Lemtrada® (alemtuzumab) at... Apr 13 2015
      Trade Europe and a Strong USD with this ETF Apr 10 2015
      Inverse Head and Shoulders Patterns Breaking Out Apr 09 2015
      What Really Happens To Stocks When The Fed Tightens Monetary Policy? Apr 08 2015
      FDA accepts Novo Nordisk's resubmitted application for insulin drug Apr 07 2015
      Sanofi: Shantha will provide up to 37 million doses of Shan5(TM) Apr 07 2015

      Add Notes, Comments

      If you want to ask a question, or report a bug, please create a support ticket.

      User Comments

      No comment yet
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      FEEDBACK